SAB Biotherapeutics, Inc. Common Stock SABS
i
Market datapartial · fetched 2026-11-12T02:43:24.687Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:00.5842495Z
FundamentalsAlpha Vantage · unavailable
SAB Biotherapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | 4.02 | 462.9% | 19.4% | |||
| 55Δ | 4.26 | 439.3% | 17.2% | |||
| 60Δ | 4.80 | 781.9% | 88.8% | 4.50 | 415.7% | 15.0% |
| 65Δ | 3.66 | 675.2% | 53.4% | 4.73 | 392.1% | 12.8% |
| 70Δ | 2.98 | 611.1% | 34.1% | 4.97 | 368.5% | 10.6% |
| 75Δ | 2.62 | 680.8% | 31.8% | 5.21 | 344.9% | 8.4% |
| 80Δ | 2.26 | 750.6% | 29.5% | 5.45 | 321.3% | 6.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.02
- IV
- 462.9%
- B/E move
- 19.4%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.26
- IV
- 439.3%
- B/E move
- 17.2%
60Δ
- Pseudo strike
- 4.80
- IV
- 781.9%
- B/E move
- 88.8%
- Pseudo strike
- 4.50
- IV
- 415.7%
- B/E move
- 15.0%
65Δ
- Pseudo strike
- 3.66
- IV
- 675.2%
- B/E move
- 53.4%
- Pseudo strike
- 4.73
- IV
- 392.1%
- B/E move
- 12.8%
70Δ
- Pseudo strike
- 2.98
- IV
- 611.1%
- B/E move
- 34.1%
- Pseudo strike
- 4.97
- IV
- 368.5%
- B/E move
- 10.6%
75Δ
- Pseudo strike
- 2.62
- IV
- 680.8%
- B/E move
- 31.8%
- Pseudo strike
- 5.21
- IV
- 344.9%
- B/E move
- 8.4%
80Δ
- Pseudo strike
- 2.26
- IV
- 750.6%
- B/E move
- 29.5%
- Pseudo strike
- 5.45
- IV
- 321.3%
- B/E move
- 6.3%
Options history
No recorded observations
Biotechnology
SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
More →SEPN
Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform. The company combines…
More →SGMT
Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases, particularly non-alcoholic…
More →SION
Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders, notably Alzheimer's and Parkinson's…
More →SLDB
Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. The company is headquartered in…
More →SLN
Description unavailable
More →